Benefits
Breaks down histamine from food in the gut
DAO is the body's main enzyme for degrading histamine in the digestive tract. Taken before a meal, supplemental DAO is intended to break down some histamine from histamine-rich foods in the gut before it is absorbed; whether enough active enzyme reaches the small intestine has not been shown in people. It works only on histamine in the gut, not on histamine already circulating in the body.
Support for people sensitive to histamine-rich foods
Small studies in people who react to histamine-rich foods have reported fewer or milder symptoms with DAO before meals, including an open-label study of 28 people and a placebo-controlled histamine challenge in which total symptom scores were lower with DAO. The open-label study had no control group and was supported by the capsule maker, and a German-Swiss-Austrian allergy-society guideline says the challenge study did not meet its primary endpoint. The same challenge study found single symptoms could not be reliably reproduced, and the condition remains hard to diagnose.
Headache duration in people with low DAO activity
In a randomized double-blind trial of 100 people with episodic migraine and low DAO activity, attacks shortened from about 6.1 to 4.8 hours over one month on DAO, but attacks on placebo also shortened and the difference between groups was not significant. The share of people using triptans fell only in the DAO group. This does not show that DAO prevents headaches in general.
Other symptom scores in small trials
In a crossover trial of 20 people with chronic hives on antihistamines, DAO lowered symptom scores versus placebo in those with low DAO levels. A 100-woman fibromyalgia trial found both groups improved, with somewhat better scores on DAO, and a 101-person sleep trial in AOC1 gene-variant carriers found no difference in the main insomnia score. None of this establishes DAO as a treatment.
Mechanism of action
Oxidative breakdown of histamine
DAO (a copper-dependent amine oxidase, also called AOC1) removes the amino group from histamine, converting it to an inactive aldehyde. In the gut wall this is the first-line route for clearing histamine that comes from food, before it can enter the bloodstream.
Works in the gut, not the bloodstream
Swallowed DAO is itself a protein and is not absorbed intact in meaningful amounts; it acts on histamine within the digestive tract. This is why it is taken right before meals and why it does not lower histamine already circulating in the body or replace antihistamine medicines.
The DAO-deficiency rationale
People with low DAO activity, whether from genetics (AOC1 variants), gut damage, or DAO-blocking drugs and alcohol, are thought to clear dietary histamine poorly. Supplemental DAO is meant to compensate at mealtimes. Serum DAO activity is used in research to identify likely responders, though its value as a diagnostic test is debated; a 2021 German-Swiss-Austrian allergy guideline states that measuring DAO activity in serum 'has no diagnostic value.'
Clinical trials
Randomized, double-blind, placebo-controlled trial of a DAO enzyme supplement for one month in migraine patients with low DAO activity, from a Barcelona group that includes a DAO-deficiency clinic (Izquierdo-Casas et al. 2019, Clin Nutr)
100 adults with episodic migraine and serum DAO activity below 80 HDU/ml; DAO or placebo for one month.
Attack duration fell from 6.14 to 4.76 hours on DAO (p=0.0217 within the group) and from 7.53 to 6.68 hours on placebo (not significant); the authors say the placebo change may explain the lack of a significant difference between groups. Number of attacks and pain intensity fell similarly in both groups. The share of patients taking triptans fell only in the DAO group, and no adverse effects were recorded.
Double-blind, placebo-controlled crossover study of DAO, one capsule twice daily 15 minutes before meals for 30 days, added to antihistamines (Yacoub et al. 2018, Int Arch Allergy Immunol)
22 adults with chronic spontaneous urticaria not fully controlled by antihistamines; 20 completed.
In patients with low serum DAO, the weekly urticaria activity score fell by 3.8 points with DAO, a significant difference from placebo (p=0.041), and improvement was larger the lower the starting DAO level. Antihistamine use dropped slightly (p=0.049). Small and short; DAO was an add-on, not a replacement.
Randomized, double-blind, placebo-controlled crossover histamine-provocation study at four Austrian centers in patients with suspected histamine intolerance (Komericki et al. 2011, Wien Klin Wochenschr)
39 patients who reacted to an open 75 mg histamine challenge entered the blinded part.
Oral histamine challenge failed to reproduce patients' individual symptoms, which argues that single-symptom provocation is not a sound way to confirm histamine intolerance. On the global measure, total symptom scores were significantly lower with DAO than with placebo (p = 0.014). The study questions single-symptom challenges as a diagnostic test while still showing a signal for the enzyme.